Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Herceptin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

Boehringer says Avastin biosimilar on track as Phase III gets underway

Boehringer says Avastin biosimilar on track as Phase III gets underway Avastin has been on the market since 2004 and along with breast cancer drug Herceptin (trastuzumab) has been the mainstay of Roche's cancer portfolio, bringing in nearly $7bn in sales

Pfizer’s first-in-class breast cancer therapy wins EU licence

Pfizer’s first-in-class breast cancer therapy wins EU licence A number of metastatic breast cancer treatments have been rejected by the UK cost-effectiveness watchdog over the last few years, including GlaxoSmithKline's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab),

Deal Watch October 2016

Deal Watch October 2016 Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development.

Roche in "unprecedented" launch period for new medicines

Roche in The star in Roche's show was once again its trio of HER2-positive breast cancer drugs - Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - whose sales increased 9% to ... 12bn francs, driven mainly by a 31% growth for

Amgen claims first US go-ahead for Humira biosimilar

Amgen claims first US go-ahead for Humira biosimilar Other biosimilars in the company's late-stage pipeline include versions of Roche's breast cancer drug Herceptin (trastuzumab) and colorectal and lung cancer therapy Avastin (bevacizumab).

[ Previous 5 results ] 8 9 10 11 12 13 14 15 16 17 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics